Obe-cel for progressive multiple sclerosis that is getting worse
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new treatment called obe-cel, a type of CAR T-cell therapy, for people with progressive multiple sclerosis that hasn't responded to other treatments. It aims to see if this therapy can slow or stop the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with progressive multiple sclerosis (MS that is getting worse).
- You have tried at least 2 MS treatments in the past.
- You do not have highly active MS or another autoimmune brain condition.
- You do not have a current serious infection, cancer, or history of an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests a new way to treat primary progressive multiple sclerosis (PPMS) using a stem cell transplant from a healthy donor. The goal is to see if this approach can stop or slow the disease and improve quality of life.
This program provides access to an already-made dose of obe-cel (a type of CAR T-cell therapy) for patients whose manufactured product didn't meet the usual standards but is still considered safe and appropriate by their doctor and the study team. It's for people with a type of blood cancer called B-cell ALL that has come back or not responded to treatment.
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.